[Controlled clinical study of the herpes antigens LUPIDON H and LUPIDON G].
Results gained in a placebo-controlled, clinical double-blind study with the Herpes antigens LUPIDON H and Lupidon G are reported. Due to treatment with LUPIDON H or LUPIDON G a cure or a more soothed course of the disease and among the indicated effects a prolongation in length of the intervals during which no relapses occurred could be observed with regard to about 80% of all the patients concerned. In opposition to the mentioned effectiveness the treatment success becoming evident after the administration of Placebo under equal test conditions was only evaluated with a rate complying to approximately 30%. The difference determined at those investigations with reference to the efficacy of LUPIDON (80%) in comparison with Placebo (30%) is statistically significant. This outcome confirms the results already observed hitherto in open clinical investigations by other examiners whose findings, too, ascribed to LUPIDON a favourable influence on Herpes simplex diseases in about 80% of treatment cases.
D000956:Antigens, Viral / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006561:Herpes Simplex / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008297:Male; D010919:Placebos; D018139:Simplexvirus / Q000276:immunology*
D000956:Antigens, Viral; D010919:Placebos
Kontrollierte klinische Studie mit den Herpes-Antigenen LUPIDON H und LUPIDON G.